EUVIMEDEUVIMED entdecken
Open Access

Proliferation and Apoptosis Adaptor Protein 15 (PEA15), a Potential Oncogenic Regulator of VHL and HIF1A Identified through Proteomic Analysis in Hepatocellular Carcinoma

Yun Seong Jeong, Ji-Hyun Shin, Soo Mi Kim, Bo Hwa Sohn, Sun Young Yim, Ji Hoon Kim, Jae Jun Shim, Sung Hwan Lee, Yun Shin Chun, Sunyoung S Lee, Hui Dai, Ahmed Kaseb und 7 weitere

Cancer Communications · 01.01.2026 · 46

DOI: 10.34133/cancomm.0020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Communications, online erschienen am 08.04.2026. Verfasst von Yun Seong Jeong und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Von Hippel-Lindau Tumor Suppressor Protein, Liver Neoplasms, Hypoxia-Inducible Factor 1, alpha Subunit. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute, Duncan Family Institute for Cancer Prevention and Risk Assessment.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally. Although the hypoxia-inducible factor 1A (HIF1A) pathway is crucial in HCC progression, its regulatory mechanisms remain unclear as mutations in its primary regulator, von Hippel–Lindau tumor suppressor ( VHL ), are rare in HCC. We aimed to elucidate the role of proliferation and apoptosis adaptor protein 15 (PEA15), identified through proteomic analysis, as a regulator of the VHL/HIF1A pathway and a therapeutic target in HCC.

Methods

Proteomic and genomic analyses of over 1,000 HCC samples were conducted, identifying PEA15 amplification. Functional validation involved in vitro and in vivo assays, including gene knockdown, ectopic expression, and antisense oligonucleotide (ASO) therapy in xenograft models. Protein interactions were assessed using immunoprecipitation and ubiquitination assays.

Results

We identified 3 clinically distinct HCC subtypes and found that PEA15 was selectively amplified and highly expressed in the mesenchymal (MES) subtype, which exhibited the poorest prognosis. PEA15 acted as a regulator of the VHL/HIF1A pathway and a key oncogene in HCC. The amplification of PEA15 was significantly associated with the poor survival of HCC patients. Moreover, by interacting with the β-domain of VHL, PEA15 promoted HCC cell proliferation and migration by inhibiting VHL’s interaction with the VHL/elongin C (ELOC)/elongin B (ELOB)/cullin 2 (CUL2) E3 ligase complex, destabilizing the complex and consequently activating HIF1A. Importantly, pharmacologically inhibiting PEA15 using PEA15 ASO drugs attenuated tumor burden and restored VHL function in a xenograft mouse model.

Conclusions

This study identified PEA15 as a potential oncogene in HCC, regulating the VHL/HIF1A axis and driving tumor progression. Targeting PEA15 using ASOs offers a promising therapeutic strategy for HCC, particularly in the MES subtype. These findings provide a basis for further exploration of PEA15 -targeted therapies to improve HCC outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularVon Hippel-Lindau Tumor Suppressor ProteinLiver NeoplasmsHypoxia-Inducible Factor 1, alpha SubunitApoptosis Regulatory ProteinsIntracellular Signaling Peptides and ProteinsHumansAnimalsMiceCell ProliferationProteomicsCell Line, TumorGene Expression Regulation, NeoplasticMaleMice, NudeFemale

Substanzen

Von Hippel-Lindau Tumor Suppressor ProteinHypoxia-Inducible Factor 1, alpha SubunitVHL protein, humanHIF1A protein, humanPEA15 protein, humanApoptosis Regulatory ProteinsIntracellular Signaling Peptides and Proteins

Autor:innen und Institutionen

  • Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Department of Physiology, Institute of Medical Science, Jeonbuk National University Medical School, Jeonju, Jeonbuk, Korea.
  • Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Kyung Hee University Hospital, Seoul, Korea.
  • Division of Hepatobiliary and Pancreas, Department of Surgery, CHA Bundang Medical Center, CHA University, Sungnam, Korea.
  • Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

ORCID-Profile: Ju-Seog Lee

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • Duncan Family Institute for Cancer Prevention and Risk Assessment
  • University of Texas MD Anderson Cancer Center

Zitieren

APA

Jeong, Y. S., Shin, J. H., Kim, S. M., Sohn, B. H., Yim, S. Y., Kim, J. H., Shim, J. J., Lee, S. H., Chun, Y. S., Lee, S. S., Dai, H., Kaseb, A., Kang, K. J., Eltzschig, H. K., MacLeod, A. R., Luo, X., Revenko, A., Kim, Y., & Lee, J. S. (2026). Proliferation and Apoptosis Adaptor Protein 15 (PEA15), a Potential Oncogenic Regulator of VHL and HIF1A Identified through Proteomic Analysis in Hepatocellular Carcinoma. Cancer Communications, 46. https://doi.org/10.34133/cancomm.0020

Vancouver

Jeong YS, Shin JH, Kim SM, Sohn BH, Yim SY, Kim JH, et al. Proliferation and Apoptosis Adaptor Protein 15 (PEA15), a Potential Oncogenic Regulator of VHL and HIF1A Identified through Proteomic Analysis in Hepatocellular Carcinoma. Cancer Communications. 2026;46. doi:10.34133/cancomm.0020

BibTeX
@article{Jeong2026,
  author = {Jeong, Yun Seong and Shin, Ji-Hyun and Kim, Soo Mi and Sohn, Bo Hwa and Yim, Sun Young and Kim, Ji Hoon and Shim, Jae Jun and Lee, Sung Hwan and Chun, Yun Shin and Lee, Sunyoung S and Dai, Hui and Kaseb, Ahmed and Kang, Koo Jeong and Eltzschig, Holger K and MacLeod, A Robert and Luo, Xiaolin and Revenko, Alexey and Kim, Youngsoo and Lee, Ju-Seog},
  title = {Proliferation and Apoptosis Adaptor Protein 15 (PEA15), a Potential Oncogenic Regulator of VHL and HIF1A Identified through Proteomic Analysis in Hepatocellular Carcinoma},
  journal = {Cancer Communications},
  year = {2026},
  volume = {46},
  doi = {10.34133/cancomm.0020}
}
Kostenlos starten →